Page 16 of 39 · 913 questions tagged clinical-trials.
What I have: REDEFINE-1 · nausea · 50 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
What I am working with: FLOW · dizziness · 10 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the…
The specifics, since they change the answer: SOUL · ecnoglutide. I would like to know whether this claim survives contact with evidence. If the answer is "nobody has…
Numbers first: ATTAIN-1 · hair thinning. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
Concretely: SUSTAIN-6 · 30 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which I…
What I am working with: SELECT · mazdutide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including…
What I have: STEP 2 · nausea · 50 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
Stated plainly: retatrutide · survodutide. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain either…
Concretely: PIONEER-1 · tirzepatide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…
Details up front: SURMOUNT-1 · dulaglutide. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am…
Orforglipron is described as a non-peptide oral GLP-1 receptor agonist, which I take to mean it is a conventional small molecule rather than a peptide with a delivery…
What I am working with: SELECT · 15 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including the…
Conditions: semaglutide · SURMOUNT-2. This is one of those things that everyone repeats and nobody derives. This matters practically, not just academically, because…
Numbers first: STEP 4 · orforglipron. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence exists…
Numbers first: SURMOUNT-OSA · orforglipron. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
Stated plainly: STEP 1 · vomiting · 10 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including…
What I have: ESSENCE · retatrutide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence exists and…
Details up front: vomiting · retatrutide · SURPASS-3. This is presented as though it settles something, and I am not convinced it does. I have two documents that…
Stated plainly: orforglipron · SURPASS-3. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody knows, I would rather hear…
Details up front: mazdutide · REDEFINE-1. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know how…
What I have: STEP 3 · 40 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s interpretation…
I have three data points across nine months, which I hope is enough to see a trend. I would rather understand the derivation than memorise the outcome. Two people I…
I have looked for a randomised comparison of dosing frequency within a single molecule in this class and cannot find one. Every phase 3 trial I can find fixed the…
What I have: mazdutide · 30 °C. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am interested in…